Apollon Wealth Management LLC Purchases 380 Shares of Veeva Systems Inc. (NYSE:VEEV)

Apollon Wealth Management LLC boosted its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 17.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,552 shares of the technology company’s stock after acquiring an additional 380 shares during the quarter. Apollon Wealth Management LLC’s holdings in Veeva Systems were worth $537,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Veeva Systems by 72.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock worth $25,000 after buying an additional 50 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new position in Veeva Systems in the third quarter worth approximately $26,000. True Wealth Design LLC raised its position in Veeva Systems by 3,375.0% in the third quarter. True Wealth Design LLC now owns 139 shares of the technology company’s stock worth $29,000 after acquiring an additional 135 shares during the period. Retirement Wealth Solutions LLC purchased a new position in shares of Veeva Systems during the 4th quarter worth $31,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Veeva Systems during the 3rd quarter valued at $49,000. Institutional investors own 88.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VEEV. StockNews.com cut Veeva Systems from a “buy” rating to a “hold” rating in a report on Thursday, February 6th. Truist Financial lowered their price objective on Veeva Systems from $261.00 to $210.00 and set a “hold” rating on the stock in a research report on Monday, January 13th. Robert W. Baird increased their target price on shares of Veeva Systems from $275.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a report on Friday, January 17th. Finally, Barclays increased their price objective on shares of Veeva Systems from $260.00 to $275.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.96.

Insiders Place Their Bets

In other Veeva Systems news, SVP Jonathan Faddis sold 1,694 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $230.30, for a total transaction of $390,128.20. Following the sale, the senior vice president now owns 8,061 shares in the company, valued at approximately $1,856,448.30. The trade was a 17.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $233.26 on Thursday. The firm has a market capitalization of $37.87 billion, a price-to-earnings ratio of 57.60, a PEG ratio of 1.97 and a beta of 0.85. The stock’s 50-day simple moving average is $224.84 and its 200-day simple moving average is $215.41. Veeva Systems Inc. has a fifty-two week low of $170.25 and a fifty-two week high of $258.93.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.